Vanguard Capital Management
DWTX

Vanguard Capital Management’s Dogwood Therapeutics DWTX Stock Holding History

Vanguard Capital Management’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Hold
132,154
– – ﹤0.01% 3818
2026
Q1 		$279K Buy
+132,154
New +$389K ﹤0.01% 3760

Other funds holding DWTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's DWTX Position: Q2 2026 in Review

Vanguard Capital Management held its Dogwood Therapeutics (DWTX) position steady in Q2 2026 at 132,154 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #3818.

Vanguard Capital Management first reported a position in DWTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $279K in Q1 2026. 16 funds tracked by Wall St. Rank hold DWTX as of Q2 2026.

  • Vanguard Capital Management held 132,154 shares of Dogwood Therapeutics worth $213K as of Q2 2026.
  • Vanguard Capital Management left its Dogwood Therapeutics share count unchanged in Q2 2026.
  • Dogwood Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3818 holding.
  • Vanguard Capital Management first reported a position in Dogwood Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Dogwood Therapeutics position peaked at $279K in Q1 2026.
  • 16 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.